← Back to Search

Cognitive Behavioral Therapy

Mobile CBT + tDCS for Chronic Pain after Bone Sarcoma

N/A
Recruiting
Led By Tara Brinkman, Phd
Research Sponsored by St. Jude Children's Research Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 8 weeks from start of feasibility study

Summary

This trial aims to help childhood cancer survivors who have chronic pain by using a special therapy app and a device that sends mild electrical currents to the brain. The therapy app is designed to be culturally sensitive for better effectiveness. The study will test if this combined approach can improve pain management in these patients.

Who is the study for?
This trial is for non-Hispanic Black and Hispanic survivors of pediatric bone sarcoma, aged 10-17 years, who are at least one year post-treatment. They must experience chronic pain that affects their daily life. Adults can participate if they're a survivor or parent of a survivor, over 18 years old.
What is being tested?
The study is testing a mobile Cognitive Behavior Therapy (CBT) program adapted for cultural relevance, combined with either real or sham Transcranial Direct Current Stimulation (tDCS). The goal is to see if this combination helps manage chronic pain in adolescent cancer survivors.
What are the potential side effects?
Possible side effects may include discomfort from the tDCS device like itching or tingling on the scalp, fatigue after therapy sessions, and potential emotional distress from discussing painful experiences during CBT.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 8 weeks from start of feasibility study
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 weeks from start of feasibility study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anxiety
Cancer-related worry
Depression
+11 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: InterviewExperimental Treatment1 Intervention
Participants attend virtual meetings and virtual focus groups during the cultural adaptation phase. Feedback is collected and analyzed to develop the finalized adaptation.
Group II: Arm I (mobile CBT + active tDCS)Experimental Treatment3 Interventions
Participants receive mobile CBT and undergo active tDCS to the dorsolateral prefrontal cortex (DLPFC) over 20 minutes twice a week for 6 weeks.
Group III: Arm II (mobile CBT + sham tDCS)Placebo Group3 Interventions
Participants receive mobile CBT and undergo sham tDCS to the DLPFC over 20 minutes twice a week for 6 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Behavior Therapy
2010
Completed Phase 3
~2630
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for bone sarcoma include surgery, chemotherapy, and radiation therapy. Surgery involves the physical removal of the tumor, chemotherapy uses drugs to kill cancer cells or stop them from growing, and radiation therapy uses high-energy rays to target and destroy cancer cells. The trial studying Culturally Adapted Mobile CBT and active tDCS focuses on non-pharmacological approaches to manage chronic pain. CBT helps patients develop coping strategies and change pain-related thoughts, while tDCS modulates brain activity to reduce pain perception. Understanding these mechanisms is crucial for bone sarcoma patients as it provides comprehensive pain management options, potentially improving their quality of life and functional ability.
Quality of life, functional ability and physical activity after different surgical interventions for bone cancer of the leg: A systematic review.Experimental study of paraplegia caused by spinal tumors: an animal model of spinal tumors created by transplantation of VX2 carcinoma.

Find a Location

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor
443 Previous Clinical Trials
5,305,423 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,811 Previous Clinical Trials
8,161,183 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,917 Previous Clinical Trials
41,014,390 Total Patients Enrolled

Media Library

Cognitive Behavior Therapy (Cognitive Behavioral Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05746429 — N/A
Bone Sarcoma Research Study Groups: Arm I (mobile CBT + active tDCS), Arm II (mobile CBT + sham tDCS), Interview
Bone Sarcoma Clinical Trial 2023: Cognitive Behavior Therapy Highlights & Side Effects. Trial Name: NCT05746429 — N/A
Cognitive Behavior Therapy (Cognitive Behavioral Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05746429 — N/A
~29 spots leftby Nov 2025